Alnylam Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alnylam Pharmaceuticals Inc.
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
In accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- Regulus Therapeutics, Inc.
- Sirna Therapeutics, Inc. Alnylam U.S., Inc Ribopharma AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.